指南与共识乳腺癌

乳腺癌人表皮生长因子受体2检测:ASCO-美国病理学家学会指南更新

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.
指南 / 共识 · J Clin Oncol · 2023-06-07

本指南更新基于系统文献综述,检索到173篇摘要,审查5篇潜在出版物后认为无信号需修订2018年ASCO-CAP的HER2检测推荐,故予以确认。更新承认德曲妥珠单抗新适应证(IHC 1+或2+且原位杂交无扩增),并新增报告注释以区分IHC 0与1+。

要点

  • 2018年ASCO-CAP的HER2检测推荐被确认。
  • 德曲妥珠单抗新适应证包括IHC 1+或2+且无扩增。
  • 新增报告注释强调IHC 0与1+区分的临床相关性。

核心结论

  • 2018年ASCO-CAP的HER2检测推荐被确认。
  • 更新承认德曲妥珠单抗用于HER2未过表达或扩增但IHC 1+或2+且原位杂交无扩增的新适应证。
  • 当前数据不支持以IHC 0与1+作为预后或预测阈值的修订。
  • 新增HER2检测报告注释以强调IHC 0与1+区分的临床相关性。

研究设计与样本

  • 更新专家组通过系统文献综述识别修订推荐的信号。
  • 检索共识别173篇摘要,审查5篇潜在出版物。
  • 审查后认为无出版物构成修订现有推荐的信号。

主要发现

  • 检索识别173篇摘要。
  • 审查5篇潜在出版物,无构成修订现有推荐的信号。
  • 德曲妥珠单抗新适应证针对IHC 1+或2+且原位杂交无扩增的乳腺癌。
  • IHC 0肿瘤的临床试验数据有限(被DESTINY-Breast04排除)。
  • 缺乏证据表明这些癌症行为不同或对新型HER2 ADC反应不同。

关键数值与推荐

  • 2018年ASCO-CAP的HER2检测推荐被确认。
  • 德曲妥珠单抗的适应证包括IHC 1+或2+且原位杂交无扩增。
  • 当前数据不支持建立IHC 0与1+的预后或预测阈值。
  • 新增HER2检测报告注释以强调IHC 0与1+区分的临床相关性。
  • 提供最佳实践建议以区分IHC 0与1+的细微差异。

临床怎么用

  • 本更新确认先前HER2报告推荐。
  • 新增HER2检测报告注释以强调IHC 0与1+结果的当前相关性。
  • 提供最佳实践建议以区分IHC 0与1+的细微差异。
  • 区分IHC 0与1+的最佳实践具有临床相关性。

局限性

  • IHC 0肿瘤的临床试验数据有限(被DESTINY-Breast04排除)。
  • 缺乏证据表明这些癌症行为不同或对新型HER2 ADC反应不同。
  • 当前数据不支持建立IHC 0与1+的预后或预测阈值。
  • 创建新的HER2表达结果类别(如HER2-Low、HER2-Ultra-Low)为时过早。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To update ASCO-College of American Pathologists (CAP) recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer. The Panel is aware that a new generation of antibody-drug conjugates (ADCs) targeting the HER2 protein is active against breast cancers that lack protein overexpression or gene amplification. METHODS: An Update Panel conducted a systematic literature review to identify signals for updating recommendations. RESULTS: The search identified 173 abstracts. Of five potential publications reviewed, none constituted a signal for revising existing recommendations. RECOMMENDATIONS: The 2018 ASCO-CAP recommendations for HER2 testing are affirmed. DISCUSSION: HER2 testing guidelines have focused on identifying HER2 protein overexpression or gene amplification in breast cancer to identify patients for therapies that disrupt HER2 signaling. This update acknowledges a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified but is immunohistochemistry (IHC) 1+ or 2+ without amplification by in situ hybridization. Clinical trial data on tumors that tested IHC 0 are limited (excluded from DESTINY-Breast04), and evidence is lacking that these cancers behave differently or do not respond similarly to newer HER2 ADCs. Although current data do not support a new IHC 0 versus 1+ prognostic or predictive threshold for response to trastuzumab deruxtecan, this threshold is now relevant because of the trial entry criteria that supported its new regulatory approval. Therefore, while it is premature to create new result categories of HER2 expression (eg, HER2-Low, HER2-Ultra-Low), best practices to distinguish IHC 0 from 1+ are now clinically relevant. This Update affirms prior HER2 reporting recommendations and offers a new HER2 testing reporting comment to highlight the current relevance of IHC 0 versus 1+ results and best practice recommendations to distinguish these often subtle differences.Additional information is available at www.asco.org/breast-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023. PMID: 37284804. doi:10.1200/JCO.22.02864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。